Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says

MT Newswires Live

05/16

Wave Life Sciences (WVE) is expected to present new data from its RestorAATion-2 study of WVE-006 at the ATS 2026 conference that could further strengthen confidence in its RNA editing platform, Wedbush Securities said in a note Friday.

The brokerage said in a Friday research note that the upcoming results could show a consistent improvement pattern versus earlier cohorts, including higher editing efficiency and sustained protein responses across dose groups.

The investment firm added that the data may support clinically meaningful levels of alpha-1 antitrypsin production. It added that the durability of the response could enable monthly or less frequent dosing intervals.

Wedbush has an outperform rating and a $15 price target on Wave Life Sciences.

Shares of the company were down 2.6% in Friday trading.

Price: 6.72, Change: -0.18, Percent Change: -2.61

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2635034943"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635034943\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635034943?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-16 02:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635034943","market":"hk","top_or_hot":-1,"title":"Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/WVE\">Wave Life</a> Sciences (WVE) is expected to present new data from its RestorAATion-2 study of WVE-006 at the ATS 2026 conference that could further strengthen confidence in its RNA editing platform, Wedbush Securities said in a note Friday.</p><p>The brokerage said in a Friday research note that the upcoming results could show a consistent improvement pattern versus earlier cohorts, including higher editing efficiency and sustained protein responses across dose groups.</p><p>The investment firm added that the data may support clinically meaningful levels of alpha-1 antitrypsin production. It added that the durability of the response could enable monthly or less frequent dosing intervals.</p><p>Wedbush has an outperform rating and a $15 price target on Wave Life Sciences.</p><p>Shares of the company were down 2.6% in Friday trading.</p><p>Price: 6.72, Change: -0.18, Percent Change: -2.61</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWave Life Sciences ATS Data Could Support RNA Editing Platform, Wedbush Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-05-16 02:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/WVE\">Wave Life</a> Sciences (WVE) is expected to present new data from its RestorAATion-2 study of WVE-006 at the ATS 2026 conference that could further strengthen confidence in its RNA editing platform, Wedbush Securities said in a note Friday.</p><p>The brokerage said in a Friday research note that the upcoming results could show a consistent improvement pattern versus earlier cohorts, including higher editing efficiency and sustained protein responses across dose groups.</p><p>The investment firm added that the data may support clinically meaningful levels of alpha-1 antitrypsin production. It added that the durability of the response could enable monthly or less frequent dosing intervals.</p><p>Wedbush has an outperform rating and a $15 price target on Wave Life Sciences.</p><p>Shares of the company were down 2.6% in Friday trading.</p><p>Price: 6.72, Change: -0.18, Percent Change: -2.61</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WVE","symbol_name":"Wave Life Sciences Pte. Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635034943","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635034943","pubTimestamp":1778870414,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Wave Life Sciences  is expected to present new data from its RestorAATion-2 study of WVE-006 at the ATS 2026 conference that could further strengthen confidence in its RNA editing platform, Wedbush Securities said in a note Friday.The brokerage said in a Friday research note that the upcoming results could show a consistent improvement pattern versus earlier cohorts, including higher editing efficiency and sustained protein responses across dose groups.The investment firm added that the data may support clinically meaningful levels of alpha-1 antitrypsin production. It added that the durability of the response could enable monthly or less frequent dosing intervals.Wedbush has an outperform rating and a $15 price target on Wave Life Sciences.Shares of the company were down 2.6% in Friday trading.Price: 6.72, Change: -0.18, Percent Change: -2.61","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WVE":"Wave Life Sciences Pte. Ltd","BK4139":"生物科技","BK4161":"工业机械","ATS":"ATS Corp.","BK4007":"制药","RNA":"Atrium Therapeutics","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4505":"高瓴资本持仓"},"translate_title":"Wedbush表示，Wave Life Sciences ATS数据可以支持RNA编辑平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":1.5,"WVE":1,"ATS":1.5},"content_text":"Wave Life Sciences (WVE) is expected to present new data from its RestorAATion-2 study of WVE-006 at the ATS 2026 conference that could further strengthen confidence in its RNA editing platform, Wedbush Securities said in a note Friday.The brokerage said in a Friday research note that the upcoming results could show a consistent improvement pattern versus earlier cohorts, including higher editing efficiency and sustained protein responses across dose groups.The investment firm added that the data may support clinically meaningful levels of alpha-1 antitrypsin production. It added that the durability of the response could enable monthly or less frequent dosing intervals.Wedbush has an outperform rating and a $15 price target on Wave Life Sciences.Shares of the company were down 2.6% in Friday trading.Price: 6.72, Change: -0.18, Percent Change: -2.61","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}